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 Abstract
Objectives. To provide a critical assessment of the pub-
lished literature on vulvar Paget disease and to allow indi-
vidualized approaches to affected patients.
Materials and Methods. A computerized search for studies
published in the literature up to June 2002 was carried out
using Ovid and Medline databases. We excluded single case
reports, letters to editors, and abstracts.
Results. Historical and epidemiological aspects of vulvar
Paget disease are summarized. Clinical and histopathological
data support a recent proposal to classify vulvar Paget dis-
ease into two categories, primary and secondary, with sig-
nificant clinical and prognostic implications. The treatment
for primary vulvar Paget disease is wide and deep surgical
excision. Inguinofemoral lymphadenectomy is added in the
management of invasive neoplasms. In the presence of sec-
ondary Paget disease, therapy must be directed toward treat-
ment of associated carcinoma.
Conclusions. The subclassification of vulvar Paget disease
is essential for correct clinical management and treatment.
Immunohistochemistry may assist in this important distinc-
tion. 
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E xtramammary Paget disease is a group of rare cu-taneous neoplasms with different localization and
natural history [1]. In 1874 Sir James Paget, describing
the disease of the breast that now bears his name, al-
luded to the possibility that the same entity might also
involve other parts of the body [2]. The occurrence of
extramammary Paget disease involving the penis and
scrotum was first reported in 1888 by Crocker [3], for
the perineal and anal region along with the scrotum by
Darier and Couillaud in 1893 [4], and in 1901 Du-
breuilh published the first instance of vulvar Paget dis-
ease in the British Journal of Dermatology [5].
Extramammary Paget disease is primarily a women’s
disease, with men constituting approximately 20% of
cases. Lesions are usually found in sites with a high
density of apocrine glands: vulva, penis, scrotum, anus,
perianal region, and axilla. Other regions where apo-
crine or modified apocrine sweat glands are located,
such as Moll’s glands of the eyelids and ceruminous
glands of the external ear canal, may be extramammary
Paget disease sites. The term “ectopic” extramammary
Paget disease [6] has been applied to locations where
apocrine glands are not usually found, such as the but-
tock, the lateral aspect of the back, or the lower portion
of the chest.
The most common location for extramammary Paget
disease in women is the vulva; more than 600 cases have
been reported to date. The second most common site is
the perianal region. Simultaneous presentations at dis-
tant sites are rare [7, 8].
Intraepithelial vulvar Paget disease was classified as a
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nonsquamous intraepithelial neoplasia of the vulva by
the International Society for the Study of Vulvar Disease
Terminology Committee in 1986 [9].
OBJECTIVE
The rarity of vulvar Paget disease makes it difficult to
understand its different clinicopathological and prog-
nostic characteristics from a single reported series. A
critical assessment of the studies on vulvar Paget disease
was carried out to update diagnostic concepts and to
allow individualized management strategies of affected
patients.
SOURCES, STUDIES SELECTION,
AND INTEGRATION
We conducted a computerized search using Ovid©
(Ovid Technologies©, Inc., New York, NY) and
PubMed (http://www.ncbi.nlm.nih.gov/PubMed/) Med-
line database for studies published from January 1966
to June 2002 with the search terms “Paget disease.”
References were limited to studies published in English,
pertaining to humans, and more specifically females. A
cross search using the terms “vulvar neoplasms and per-
ineum” was performed to avoid the inclusion of Paget
disease of sites other than the vulvoperineal region. We
excluded single case reports, letters to editors, and ab-
stracts. Evaluation of the bibliographies of retrieved ar-
ticles and consultation with experts in the field provided
additional references.
Relevant features were extracted from each study and
divided into the following groups: clinical aspects, his-
topathological aspects, vulvar Paget disease and invasive
neoplasms, and treatment. The review was focused on
data useful to optimize patient care.
CLINICAL ASPECTS
Patient Characteristics
Vulvar Paget disease is uncommon and accounts for
2.5% of all vulvar malignancies [10]. It affects mainly
white patients aged between 40 and 80 years. The me-
dian age is approximately 70 [10–13] both for intraep-
ithelial and invasive vulvar Paget disease patients [14].
No element in patients’ family, environmental, or social
histories suggested an etiology or propensity for devel-
oping vulvar Paget disease.
Symptomatology
Symptoms are not specific; most patients report itch-
ing, burning, and soreness. A small subset of patients
may be asymptomatic. Presence of vulvar pain, bleed-
ing, and tumor formation are reported to be more com-
mon in patients affected by invasive disease [14, 15].
Macroscopic Appearance
Vulvar Paget disease presents as a variety of clinical
lesions that may occur over a protracted course. Initially
it is velvety, soft, and red or bright pink with scattered
white islands of hyperkeratosis (Figure 1). The lesions
become erythematous, plaque like, and desquamating
especially when located in dry areas. Rarely the appear-
ance is ulcerated (Figure 2). Cases of pigmented vulvar
Paget disease are reported [16]. The borders appear ir-
regular, slightly elevated, and sharply demarcated [17,
18]. The visible borders of vulvar Paget disease are often
misleading as Paget cells may spread along the basal
layers of normal appearing skin with multicentric foci
[18–22]. Involvement may be extensive including the
perianal region, genitocrural, and inguinal folds [23].
Clinical examination should determine the presence of
periurethral and perianal lesions (Figure 3). In these
cases an involvement of the skin by a noncutaneous
internal neoplasm may occur (see below).
Figure 1. Clinical aspect of intraepithelial primary vulvar Paget
disease: an extensive erythematous slightly raised lesion with ar-
eas of hyperkeratosis involves the external genitalia and the
right genitocrural fold.
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Differential Diagnosis
Macroscopic aspects of vulvar Paget disease lesions
are often confused with lichen sclerosus, dermatophyto-
sis, candidiasis, contact dermatitis, psoriasis, seborrheic
dermatitis, and squamous vulvar intraepithelial neopla-
sia. An accurate anamnesis, a clinical examination to
search for similar lesions elsewhere on the body and a
biopsy with the appropriate use of immunohistochem-
istry, will confirm a vulvar Paget disease diagnosis.
HISTOPATHOLOGICAL ASPECTS
Histogenesis
Among the theories discussed in the literature regard-
ing the histogenesis of vulvar Paget disease [11, 24, 25]
the multifocal origin was generally accepted. This as-
sumption was based on concepts of skin embryology.
Woodruff and Kaufman hypothesized that Paget cells
derive from undifferentiated basal cells of the stratum
germinativum [26, 27], the stem cells that, except for the
melanocytes, are the origin of all the cells of the epider-
mis and its appendages [28]. This embryology-based hy-
pothesis explained the multifocal primary origin of in-
traepithelial Paget disease with or without associated
underlying adenocarcinoma and does not contradict the
fact that intraepithelial disease can remain in situ for a
long period of time before invading the dermis [17, 24,
25, 29, 30].
The origin of vulvar Paget disease from supernumer-
ary mammary glands has also been suggested [31]. Cur-
rent evidence, however, supports that these mammary-
like glands are not supernumerary mammary glands but
rather vulvar specialized anogenital glands closely re-
lated to eccrine glands [32].
Recently Wilkinson and Brown have proposed a clas-
sification of vulvar Paget disease that takes into account
its heterogenous origin. This classification defines two
distinct groups of vulvar Paget disease, those of cutane-
ous origin and those of noncutaneous origin. The latter
group includes Paget disease of urothelial, anorectal,
and other noncutaneous sites [33]. This classification is
supported by immunohistochemical studies to distin-
guish these Paget lesions and aids in understanding the
otherwise apparent conflicting findings in various re-
ports of Paget disease.
Histopathology
Vulvar Paget disease diagnosis is established through
the histologic examination of a biopsy. Pathognomonic
is the finding of atypical glandular type cells, the Paget
cells, scattered or grouped in nests within the surface
squamous epithelium [34, 35]. In routine hematoxylin
and eosin stained histologic sections, Paget cells are
rounded or polygonal elements of relatively large size
with abundant clear pale eosinophilic cytoplasm (Figure
Figure 2. Clinical aspect of primary vulvar Paget disease with
stromal invasion: ulcerated area on the left labium majus.
Figure 3. Clinical aspect of intraepithelial primary vulvar Paget
disease: perineal and perianal extension of eczematous appear-
ing lesion.
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4). The cytoplasm contains neutral and acid mucopoly-
saccharides that stain positively with mucicarmine, al-
dehyde fuchsin, Alcian blue at pH 2.5, Periodic
acid/Schiff, which is resistant to diastase digestion [17,
36], and it is usually also positive to colloidal iron and
sialomucin staining [37]. Mitotic figures do not fre-
quently occur [38].
Involvement of the pilosebaceous units and sweat
glands may be seen [34, 39–41]. The occurrence of epi-
dermal lesions adjacent to anogenital Paget disease has
been recently studied [42].
As opposed to intraepithelial vulvar Paget disease,
invasive disease shows a discontinuous basement mem-
brane in the area of invasion with groups of Paget cells
protruding into the underlying stroma [38]. These cells
appear more anaplastic and react weakly with mucicar-
mine stain [39, 41].
Differential Diagnosis
Histologic differential diagnosis of vulvar Paget dis-
ease includes pagetoid melanoma, vulvar squamous in-
traepithelial neoplasia, sebaceous carcinoma, Merkel
cell carcinoma with pagetoid intraepidermal spread, ec-
crine porocarcinoma, tricholemmal carcinoma, cutane-
ous T-cell lymphoma, Pagetoid Spitz nevus, and histio-
cytosis X [43–45].
It is crucial to exclude stromal invasion, underlying
invasive adenocarcinoma, and vulvar pagetoid spread of
associated adjacent noncutaneous adenocarcinoma that
severely affect patients’ prognosis. On routine histology
some differences can be found between Paget cells of
primary vulvar cutaneous origin and those of anorectal
and urothelial origin, with secondary vulvar spread
[33]. Immunohistochemistry will help in the diagnosis.
Immunohistochemistry
The immunohistochemical characteristics of Paget
cells in primary intraepithelial vulvar Paget disease are
summarized in Table 1 together with the characteristics
of normal skin [24, 29, 43, 46–53]. From these findings,
intraepidermal Paget cells are proved to be differenti-
ated mainly toward the ductal portion (CEA, II-7, B6.2
positivity), although in some instances partially toward
the secretory portion of the sweat glands (GCDFP-15,
CD15, PKK1 positivity). The question of whether Paget
cells show apocrine differentiation is still controversial,
but they do not show complete apocrine differentiation
nor do they show eccrine differentiation.
Immunohistochemistry provides reliable assistance in
the differential diagnosis of vulvar Paget disease against
pagetoid melanoma using S100 (a calcium-binding pro-
tein), HMB45 (a melanoma-specific cytoplasmic anti-
gen), and Melan-A as melanocytic markers [16, 54–56]
and against vulvar squamous intraepithelial neoplasia as
the panel of keratins expressed by Paget cells differs
from the cells of adjacent epidermis [57]. In particular
the strong immunoreactivity for keratins 7 and 19 fa-
cilitates the identification of small foci of intraepithelial
and invasive vulvar Paget disease lesions [58–60].
Data from the literature underline that Paget cells
in primary cutaneous vulvar Paget disease are for the
most part immunoreactive for cytokeratin 7, CEA, and
GCDFP-15 (Figure 5). Less frequently they are focally
reactive for cytokeratin 20. This immunophenotype (CK
7+, CK 20–/+, GCDFP 15+) assists in the distinction be-
tween primary vulvar Paget disease and less common
pagetoid involvement of vulvar skin by a noncutaneous
internal neoplasm. This distinction is of utmost clinical
importance as therapeutic approaches and prognoses of
these diseases are quite different, despite their similar
clinical and routine histopathologic findings.
The most common cause of noncutaneous vulvar
pagetoid involvement is perianal spread from an asso-
ciated anorectal adenocarcinoma. These cases, different
from primary vulvar Paget disease, typically express cy-
tokeratin 20 and, at the same time, immunohistochem-
ical reactions for GCDFP15 are negative [57, 60–72].
The second most common cause of noncutaneous
Paget disease is related to direct extension or intraepi-
thelial epidermotropic extension to the vulvar skin or
Figure 4. Histologic aspect of intraepithelial primary vulvar
Paget disease: typical Paget’s cells are present singly and clus-
tered in nests throughout the whole thickness of the epidermis.
The pale cytoplasm easily differentiates them from surrounding
keratinocytes (hematoxylin and eosin, original magnification
40).
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mucosa by urothelial neoplasia (Paget disease secondary
to transitional cell carcinoma of the bladder or urethra,
also referred to as pagetoid intraepithelial urothelial
neoplasia) [33, 71, 73–76]. The cells of urothelial origin
are not GCDFP-15 positive as are the Paget cells of
primary cutaneous vulvar Paget disease, but they are
immunoreactive for cytokeratin 7 and often for cytoker-
atin 20 and Uroplakin III like transitional cell carcino-
mas of the urinary tract [71, 77–80]. Immunoreactivity
for Uroplakin III was not found in any cases of primary
cutaneous vulvar disease [80].
Other cases of vulvar secondary involvement from
adenocarcinoma of the cervix, endometrium, and ovary
are described as single case reports.
Electron Microscopy
Electron microscopy shows that vulvar Paget disease
cells differ markedly in structure from the keratinocytes
of the surrounding epidermis, and cell cytoplasm ap-
pears more electron lucent. Two cell variants are pre-
sent, secretory and nonsecretory, the former being more
common with abundant secretory granules, well-
developed Golgi complex, and profiles of endoplasmic
reticulum. A small number of cells do not contain se-
Figure 5. Immunohistochemical aspect of intraepithelial primary
vulvar Paget disease: positive reaction for carcinoembryonic an-
tigen in the cytoplasm of Paget cells but not in surrounding ke-
ratinocytes (immunoperoxidase stain, original magnification
100).
Table 1. Immunohistochemical Characteristics of Paget Cells in Primary Vulvar Intraepithelial Paget Disease and in
Normal Skin
Reagent Clone name
Paget
cell
Apocrine secretory
differentiation
Eccrine secretory
differentiation
Ductal
differentiation
Sebaceous
differentiation
Epidermal
differentiation Pretreatment
Anticarcinoembryonic
antigen (CEA)
Polyclonal ++ + + +  
Anticarcinoembryonic
antigen (CEA)
II-7 ++   +   Microwave
Antibreast carcinoma
associated antigen
B6.2 ++   +  
Antihuman milk fat
globules subclass 1
(HMFG-1)
HMFG 1 ++ + + + + 
Antihuman milk fat
globules subclass 2
(HMFG-2)
HMFG 2 ++ + + + + 
Anti-BCA 225 CU18 ++ + + + + 
Antigross cystic disease
fluid protein 15
(GCDFP-15)
D6 + + +   
Anti-CD 15 Leu M1 + +    
Anti-epithelial
membrane antigen
(EMA)
E29 ++ + + +  
Antilysozyme Polyclonal  +     Protease
Antikeratin (K1) 34B4      +Suprabasal
Antikeratin (K8) 35H11 + + + +   Protease
Antikeratin (K19) Ks19.1 ++ + + +   Protease
Antikeratin PKK1 + + +   +Basal Protease
Antikeratin KL1 ++ + + +  +Suprabasal
Antikeratin AE1 ++ + + +  +Basal Protease
Anticytokeratin LP34    +  +Suprabasal Protease
Anti-Ca19.9 116-NS-19.9   + +   Microwave
Anti Ca 15.3 DF3 ++ + + + +  Microwave
++, cells positive in 80–100% of the cases; +, cells positive in 10–80% of the cases; , cells negative in almost all cases.
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cretory vacuoles and have scanty cytoplasmic organelles
[29, 81]. Cells of invasive vulvar Paget disease show the
same features as those of intraepithelial vulvar Paget
disease, with fewer secretory granules. Small desmo-
somes, which attach Paget cells to each other and to
adjacent keratinocytes, are absent in invasive neoplasms
[41, 81]. These findings are consistent with the recent
report of reduced expression of desmoglein I and pla-
koglobulin (cell-cell adhesion molecules) in invasive vul-
var Paget disease [82].
DNA Ploidy
The prognostic role of ploidy in vulvar Paget disease
has been analyzed in four different series [59, 83–85].
Twenty-five of 59 cases of intraepithelial vulvar Paget
disease (42%) were nondiploid and 8 of 21 invasive
lesions (38%) were diploid. The recurrence rate was
26% (11/42) in diploid lesions and 31% (12/38) in non-
diploid lesions. From these data we cannot infer a sig-
nificant value of tumor DNA ploidy in predicting either
recurrence or invasion.
Viruses, Oncogenes, and Tumor Markers
Some of the characteristics of vulvar Paget disease,
such as multicentricity, a tendency to recur, and rare
invasiveness, recall virus-associated epithelial atypia.
No study has evidenced human papillomavirus (HPV)
antigen or HPV DNA in the cells of vulvar Paget disease
specimens [42, 86–89], so that the participation of HPV
infection in the pathogenesis of the disease is unlikely.
On the other hand neither p53 gene mutations nor loss
of heterozygosity at selected loci were detected in Paget
cells [89]. Immunohistochemical analyses for c-erb-B2
antigen [22, 30, 90], bcl2, and p53 protein expression
[59, 84, 91, 92] have revealed conflicting and inconclu-
sive results. The role of these oncogenes is still undeter-
mined and without an actual role in indicating patients
at greater risk of recurrence or invasive neoplasm. No
data support the use of serum tumor markers SCC,
LSA, and Ca 19–9 to predict disease occurrence or re-
currence [93].
The underlying genetic defects in extramammary
Paget disease are probably different from those in other
epithelial malignancies. Further molecular genetic stud-
ies may help to cast light on the peculiar biological be-
havior of vulvar Paget disease.
VULVAR PAGET DISEASE
PROPOSED SUBCLASSIFICATION
Wilkinson and Brown have applied data on histogen-
esis, histopathological, and immunohistochemical meth-
ods as well as clinical features to subclassify vulvar
Paget disease into two main categories [33].
1. PRIMARY (of cutaneous origin) vulvar Paget disease
is subclassified:
1a) Paget disease as a primary intraepithelial neo-
plasm
1b) Paget disease as an intraepithelial neoplasm with
stromal invasion
1c) Paget disease as a manifestation of an underlying
primary adenocarcinoma of a skin appendage or
a subcutaneous vulvar gland
2. SECONDARY vulvar Paget disease (involvement of
the vulvar skin by a noncutaneous internal neo-
plasm) is subclassified in:
2a) Paget disease secondary to anal or rectal adeno-
carcinoma
2b) Paget disease secondary to urothelial neoplasia
2c) Paget disease secondary to adenocarcinomas or
related tumors of other sites
The following paragraphs will illustrate the clinical
and pathological importance of distinction between the
different vulvar Paget lesions.
VULVAR PAGET DISEASE AND
INVASIVE NEOPLASMS
In the past decades there was considerable confusion
about the relationship between vulvar Paget disease and
associated malignancies. This term has been used to in-
dicate: 1) the presence of dermal invasion; 2) association
with underlying skin appendage invasive adenocarci-
noma; and 3) association with carcinoma of adjacent
structures (vulva-vagina), regional internal organ (co-
lon-rectum, urinary tract), unrelated visceral organ
(uterus, ovary, stomach), or carcinomas at a distant site
(breast, lung) occurring before, contemporaneously, or
after vulvar Paget disease diagnosis.
In Table 2 the studies where a distinction among the
above-cited subgroups was feasible are reported [11,
13–15, 20, 23, 24, 35, 39–41, 59, 66, 67, 83–85, 93–
105].
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Primary Vulvar Paget Disease with Stromal Invasion
Dermal invasion may evolve from primary vulvar in-
traepithelial Paget disease over time. The subset of mini-
mally invasive vulvar Paget disease (stromal invasion 
1 mm) [20, 104] represents direct histologic evidence
that intraepithelial vulvar Paget disease has the potential
to invade as intraepithelial and that invasive compo-
nents are composed of the same cells with identical im-
munophenotype [59]. The development of invasive vul-
var Paget disease is reported up to 10 years after initial
treatment for intraepithelial vulvar Paget disease [20]. In
most invasive vulvar Paget disease an extensive intraep-
ithelial skin involvement ( 10 cm in diameter) is re-
ported [13], and invasion does appear to develop in an
undifferentiated area of intraepithelial disease [106].
The differing proportion of invasive vulvar Paget dis-
ease in the various series (from 0% to 48%) (Table 2)
may reflect referral bias of cases more likely to be re-
ferred to tertiary centers. Furthermore the identification
of invasive disease may be a result of more thorough
histologic sampling of the tumor [59].
Vulvar Paget Disease as a Manifestation of Primary
Underlying Adenocarcinoma of the Vulva
In mammary Paget disease almost all cases reflect the
extension of malignant cells into the epidermis, via lac-
tiferous ducts, from an underlying mammary carci-
noma: the so-called epidermotropic metastasis [1]. This
relationship is generally absent in vulvar Paget disease
and association with invasive underlying adenocarci-
noma is present in approximately 10% of cases (range =
0–40%) (Table 2). Selection bias in different series may
result from the differing surgical procedures used. Wide
vulvar excision may underestimate the presence of un-
derlying adenocarcinoma with respect to total vulvec-
tomy. A more reliable prevalence of concurrent adeno-
Table 2. Vulvar Paget Disease: Stromal Invasion, Association with Underlying Adenocarcinomas, and Other
Carcinomas Reported in the Literature
Author Ref. y
No. of
cases
No. cases
with
stromal
invasiona %
No. cases with
underlying
adenocarcinomasb %
No. cases
with other
carcinomasc %
Sited
Colon
rectum
Urinary
tract Ovary Uterus
Vulva
vagina Breast Other
Koss [39] 1968 8 0 0 2 25 4 50 1 1 1 1 1
Fenn [35] 1971 7 2 29 0 0 3 43 1 2 1
Creasman [94] 1975 15 0 0 5 33 4 27
Taylor [95] 1975 18 4 22 2 11 4 22 1 1 1 1
Tsukada [40] 1975 8 0 0 1 13 3 38 2 1
Lee [41] 1977 13 1 8 3 23 4 31 1 1 1 1
Breen [11] 1978 13 0 0 0 0 5 38 2 1 1 1
Stacy [96] 1986 13 0 0 0 0 5 38 3 1 1
Bergen [23] 1989 14 0 0 0 0 1 7 1
Curtin [97] 1990 36 1 3 5 14 9 25 1 1 2 4 3
Feuer [20] 1990 19 2 11 1 5 6 32 1 2 2 2
Ewing [98] 1991 6 0 0 1 17 0 0
Olson [24] 1991 16 6 38 3 19 1 6 1
Garzetti [99] 1992 4 1 25 0 0 0 0
Helm [100] 1992 21 0 0 2 10 5 24 5 1
Molinie [101] 1993 36 0 0 1 3 5 14 2 1 1 1 1
Baehrendtz [102] 1994 28 3 11 0 0 6 21 1 1 1 1 2
Cotton [83] 1995 14 2 14 2 14 3 21 2 1
Fishman [93] 1995 14 1 7 2 14 7 50 1 1 1 1 2 1
Kodama [14] 1995 30 9 30 11 37 2 7 1 1
Kohler [66] 1996 19 0 0 0 0 2 11 2
Tsai [103] 1996 5 1 20 2 40 0 0
Goldblum [67] 1997 19 6 32 0 0 2 11 1 1
Scheistrøen [84] 1997 34 0 0 5 15 8 24 1 2 1 5 1
Ta˚gsjo¨ [85] 1997 16 2 13 5 31 0 0
Crawford [59] 1999 21 10 48 0 0 8 38 1 2 1 3 2 1
Fanning [13] 1999 100 12 12 4 4 20 20 4 6 16
Piura [104] 1999 5 1 20 1 20 0 0
Parker [15] 2000 76 9 12 13 17 8 11 1 1 4 3 1
Zollo [105] 2000 22 6 27 1 5 8 36 1 1 5 3
Total 650 79 12 72 11 133 20 11 19 7 27 6 42 38
aAt diagnosis or during follow-up for intraepithelial disease.
bVulvar Paget disease as a manifestation of an underlying primary adenocarcinoma of a skin appendage or a subcutaneous vulvar gland.
cOccurring before, contemporaneously, or after vulvar Paget disease diagnosis.
dMultiple sites in the same patients are reported, sites are not specified in some studies.
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carcinoma (4%) may be reported from large series
where all surgical procedures were included [13]. Fur-
thermore some reports showing a high prevalence of
underlying adenocarcinoma may have included cases of
invasive vulvar Paget disease.
Primary underlying vulvar adenocarcinoma may
originate from adenocarcinoma of the Bartholin gland,
specialized anogenital glands, or other vulvar glandular
structures. Underlying adenocarcinomas are usually
clinically apparent. However, this is not invariable [20],
and thus the underlying dermis, beneath the clinically
visible Paget disease, should be removed for appropriate
histologic evaluation.
Association with Other Neoplasms
Patients with vulvar Paget disease are also reported to
be at increased risk of other primary neoplasms. The list
of associated malignancies includes anal, rectal, colonic,
endometrial, cervical ovarian and stomach adenocarci-
noma, vaginal and vulvar squamous cell carcinoma,
papillary transitional cell carcinoma of the renal pelvis,
ureter, bladder and urethra, basal cell skin cancer, lung,
breast, and thyroid carcinoma. The reported frequency
of associated malignancy is highly variable by site, type,
and temporal relationship, and it ranges from 0% to
50% (mean 20%) (Table 2). The prevalence of cancer in
these elderly patients is not significantly different from
published data for patients from their demographic
group [107], and the association of vulvar Paget disease
with cancer may be, for the most part, a secondary effect
of the advanced age of these patients [13]. To truly
evaluate whether the risk of another malignancy in
women with Paget disease is increased, one would need
to design a specific study to address this hypothesis.
Moreover, the search for additional malignancy would
have to be systematic, which it was not in most parts of
the series examined.
It should be stressed that perianal or periurethral
Paget disease may represent involvement of the vulvar
skin by pagetoid extension of a regional neoplasm in-
cluding anorectal adenocarcinoma or urothelial neopla-
sia. In these cases of secondary vulvar Paget disease im-
munohistochemical analysis demonstrates distinctive
features.
A systemic work-up for an associated malignancy
should be reserved for selected cases. An evaluation in-
cluding colon-sigmoidoscopy, urethrocystoscopy, chest
roentgenogram, intravenous pyelogram, mammogram,
cervicovaginal Pap smear, urine cytology, and CAT scan
[101] appears too extensive to be applied routinely to
patients with only vulvar localization of Paget disease.
TREATMENT
Ideal therapy aims at minimal tissue destruction and
low recurrence rate, but some features of vulvar Paget
disease interfere with these goals. The treatment and
prognosis are closely related to pathologic characteris-
tics of the disease.
Primary Vulvar Intraepithelial Paget Disease
The treatment is wide and deep surgical excision as
recommended by most authors [23, 25, 93, 108]. Wide
local excision, including a peripheral margin of 1.5–2
cm of skin with normal appearance, is not always easy
to achieve while preserving sexual function, normal
anatomy, and body image, particularly for excision of
lesions at the vaginal side near the urethral orifice. At
the same time, deep resection of the lesion is mandatory.
Not only the dermis but also all skin appendages that
could potentially contain Paget cells should be resected.
As no hair follicles or sweat glands extend more than
4.0 mm below the surface of the epidermis [23], excision
deeper than this is not recommended. Complete inclu-
sion of skin appendages and histologic examination to
search for underlying neoplasms are two reasons that
exclude laser vaporization as the sole treatment of vul-
var Paget disease [98, 109, 110]. Recently photody-
namic therapy [111] has been proposed as a primary
treatment of vulvar Paget disease using topical 20%
-aminolevulinic acid and Argon dye laser [105].
Primary Vulvar Paget Disease with Stromal Invasion
Most studies have reported that foci of superficial
dermal invasion associated with predominantly intraep-
ithelial vulvar Paget disease did not adversely affect
prognosis [14, 20, 59, 67]. The rare reports of meta-
static minimally invasive vulvar Paget disease probably
describe un-sampled deeper foci of invasion [20, 104]
and, up to now, a conservative approach in the treat-
ment of minimally invasive vulvar Paget disease is rec-
ommended. It should be emphasized that in the litera-
ture there is no consensus for the method of measure-
ment for depth of invasion in vulvar adenocarcinoma.
Vulvar Paget Disease as a Manifestation of an
Underlying Primary Cutaneous Adenocarcinoma of
the Vulva
These patients, as well as patients with stromal inva-
sion exceeding 1 mm, should be treated with vulvar
excision to the fascia of the clinically involved area and
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bilateral inguinofemoral lymphadenectomy. The clinical
course of these patients is much different from intraep-
ithelial vulvar Paget disease. They recur soon after the
initial treatment, frequently showing general metastases
[14]. It is clear that surgical treatment alone is not
enough for these patients because micrometastases seem
to exist at the time of surgical excision [14, 94]. For
these patients effective systemic therapy is indicated.
Vulvar Paget Disease as Involvement of the Vulvar
Skin by a Noncutaneous Internal Neoplasm
In such cases therapy is directed toward treatment of
the associated carcinoma, and vulvar Paget disease can
be treated with a conservative approach like an intraep-
ithelial lesion. The prognosis depends on the stage and
prognostic factors of the associated adenocarcinoma.
Integrated Therapies
There are few data in the literature on radiotherapeu-
tic or chemotherapeutic approaches to locally advanced,
recurred, or invasive vulvar Paget disease. The small
number of patients treated with chemotherapy (topical
bleomycin, mitomycin-C, 5-fluorouracil, cyclophospha-
mide, doxorubicin, cisplatin, carboplatin, vincristine) as
yet allows for no final conclusions about the regimens
proposed [14, 112]. Clear inclusion criteria and ad-
equate follow-up time are required to clarify the role of
radiation therapy for patients who are not surgical can-
didates [113–115]. The clinical evidence does not sup-
port the use of chemotherapy and radiotherapy for pa-
tients with intraepithelial vulvar Paget disease not asso-
ciated with invasive carcinoma.
A recent study demonstrated that vulvar Paget dis-
ease cells express androgen receptors rather than estro-
gen or progesterone receptors [116]. Further studies are
needed to determine whether androgen receptor status
could aid in the therapy of recurrent and invasive vulvar
Paget disease.
Margin Control
In primary vulvar Paget disease the clinical visible
borders do not completely define the histologically in-
volved area. Therefore a balance between the extent of
surgical resection and the probability of leaving Paget
cells in the remaining vulvar tissue is difficult to deter-
mine. Various types of margin controls have been pro-
posed to reduce local recurrence, including colposcopi-
Table 3. Intraepithelial Vulvar Paget Disease and Local
Recurrrence after Therapy (not considered patients lost
to follow-up or that refused primary treatment)
Author Ref. y
No. of
cases
No. cases
recurred
%
Recurrences
No. cases
dead of
disease
Koss [39] 1968 5 0 0 0
Fenn [35] 1971 7 1 14 0
Taylor [95] 1975 14 7 50 0
Tsukada [40] 1975 7 1 14 0
Lee [41] 1977 9 2 22 0
Breen [11] 1978 13 2 15 0
Stacy [96] 1986 13 1 8 0
Bergen [23] 1989 14 3 21 0
Curtin [97] 1990 28 6 21 0
Feuer [20] 1990 15 8 53 0
Olson [24] 1991 10 2 20 2a
Garzetti [99] 1992 4 1 25 0
Molinie [101] 1993 29 11 38 0
Baehrendtz [102] 1994 21 11 52 3a
Cotton [83] 1995 10 3 30 0
Fishman [93] 1995 14 5 36 0
Kodama [14] 1995 10 3 30 0
Kohler [66] 1996 14 9 64 0
Tsai [103] 1996 2 0 0 0
Goldblum [67] 1997 14 4 29 1a
Scheistrøen [84] 1997 29 8 28 0
Ta˚gsjo¨ [85] 1997 10 4 40 0
Crawford [59] 1999 11 5 45 0
Fanning [13] 1999 84 30 36 0
Piura [104] 1999 3 1 33 0
Parker [15] 2000 44 16 36 0
Zollo [105] 2000 15 5 33 0
Louis-Sylvestre [110] 2001 49 22 45 0
Total 498 171 34 6a
aPatients progressed to invasive adenocarcinoma during follow-up for intraepithelial
vulvar Paget disease.
Table 4. Vulvar Paget Disease with Stromal Invasion or
Associated with Underlying Invasive Adenocarcinoma
and Local Recurrence after Therapy (not considered
patients lost to follow-up or that refused
primary treatment)
Author Ref. y
No.
of
cases
No.
cases
recurred
%
Recur-
rences
No. cases
dead of
disease
% Dead
of
disease
Koss [39] 1968 2 2 100 0 0
Parmley [106] 1975 7 5 71 5 71
Taylor [95] 1975 4 4 100 4 100
Lee [41] 1977 4 1 25 0 0
Curtin [97] 1990 5 3 60 2 40
Feuer [20] 1990 2 1 50 1 50
Olson [24] 1991 6 3 50 1 17
Baehrendtz [102] 1994 3 3 100 3 100
Cotton [83] 1995 4 1 25 0 0
Kodama [14] 1995 20 10 50 7 35
Tsai [103] 1996 2 1 50 1 50
Goldblum [67] 1997 5 1 20 0 0
Scheistrøen [84] 1997 5 3 60 3 60
Ta˚gsjo¨ [85] 1997 6 3 50 2 33
Crawford [59] 1999 10 3 30 1 10
Fanning [13] 1999 16 4 25 0 0
Piura [104] 1999 2 1 50 0 0
Parker [15] 2000 22 13 59 1 5
Zollo [105] 2000 5 3 60 0 0
Total 130 65 50 31 24
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cally directed multiple biopsies, intraoperative intrave-
nous fluorescin with ultraviolet light scanning, and
frozen section. All of these techniques have been re-
ported as successful methods and all have limitations
[19, 21, 96, 117, 118]. A false-negative rate of approxi-
mately 35% in delineating surgical margins is reported
for both frozen sections and visual observation [93] be-
cause of the presence of irregular boundaries and skip
lesions [19, 96]. There is, however, no evidence that
intraoperative frozen section margin assessment reduces
recurrence or improves survival [93]. Even antibodies to
carcinoembryonic antigen, epithelial membrane antigen,
and low molecular weight cytokeratins, used to improve
Paget cell detection sensitivity, add no value in identify-
ing Paget cells in resection margins that are negative on
routine hematoxylin and eosin staining [119].
Recurrences
The difficulty in defining the margins of vulvar Paget
disease lesion extension is closely related to the problem
of recurrences: an apparently complete excision of in-
traepithelial vulvar Paget disease is followed by recur-
rences, even in skin grafts used to cover the wound after
vulvectomy [120]. Patients with recurrent disease are
characterized by multiple recurrences [97]. Almost half
of the recurrences appear within 18 months from initial
treatment [102] with a range from a few months to
more than 15 years [13, 15, 83, 101].
Difficulties in comparing reports arise from the dif-
ferent types of surgical procedures performed and from
the state of operative margins, which are often not de-
tailed. The recurrence rate of 15–20% in cases with
negative margins increases to 50% or more if surgical
margins are involved. Furthermore the mean time to
recurrence for patients with negative margins is longer
than for those with positive margins [14, 15, 59, 93,
101]. The surgical resection of visibly involved skin and
mucosa, with visibly normal skin margins of resection,
without frozen section assessment, is a reasonable and
effective approach to vulvar cutaneous Paget disease
[93]. As the frequency of local recurrence is strongly
correlated with the presence of invasive disease [15] we
reported in separate tables intraepithelial (Table 3) [11,
13–15, 20, 23, 24, 35, 39–41, 59, 66, 67, 83–85, 93,
95–97, 99, 101–105, 110] and invasive (Table 4) [13–
15, 20, 24, 39, 41, 59, 67, 83–85, 95, 97, 102–106]
vulvar Paget disease series.
Because most recurrences of intraepithelial vulvar
Paget disease consist entirely of intraepidermal disease,
which does not affect survival [7], and the extent of the
initial operation does not correlate with disease recur-
rence, conservative local excision for intraepithelial le-
sions is a reasonable consideration in young and old
patients.
CONCLUSION
The use of biopsies for any unclear vulvar abnormal-
ity gives valuable information at a reasonable cost and
prevents delay of diagnosis. When diagnostic difficulty
occurs, immunohistochemical studies can be used. The
recently proposed vulvar Paget disease subclassification
will contribute to the correct diagnosis and appropriate
treatment for affected patients. Prognosis is closely re-
lated to pathologic characteristics of the disease. Addi-
tional molecular genetic studies are needed to better un-
derstand the biological behavior of vulvar Paget disease.
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